-
- Aditya K. Gupta
- Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook site) and the University of Toronto, Toronto, Canada
-
- Melanie Browne
- Mediprobe Laboratories Inc., Toronto, Ontario, Canada
-
- Robyn Bluhm
- Mediprobe Laboratories Inc., Toronto, Ontario, Canada
説明
<jats:sec><jats:title>Background and Objective:</jats:title><jats:p> Imiquimod (Aldara) is an immune response modifier used primarily to treat anogenital warts. Imiquimod induces cytokines and enhances cell-mediated cytolytic antiviral activity in vivo. It exhibits antiviral and antitumor effects; however, it does not exhibit direct antiviral effects in vitro. By inducing cytokines, such as interferon A, imiquimod stimulates both the innate immune response and the cellular arm of acquired immunity. Currently, imiquimod is approved for use in the treatment of external genital and perianal warts in adults. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Beyond its established use, there are case reports and preliminary studies suggesting the effectiveness of imiquimod 5% cream in the treatment of nongenital human papillomavirus warts, molluscum contagiosum, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, Bowen's disease, nongenital human papillomavirus infection, and vulvar intraepithelial neoplasia. </jats:p></jats:sec>
収録刊行物
-
- Journal of Cutaneous Medicine and Surgery
-
Journal of Cutaneous Medicine and Surgery 6 (6), 554-560, 2002-11
SAGE Publications
